@jeremycorbyn As a Palestinian-Israeli I tell you:
No ceasefire until Hamas is eliminated.
It’s for a better future for both Israelis and Palestinians.
When you ask for a ceasefire you’re asking to save Hamas. We want a good future for all our children. Don’t ruin it.
#FreePalestineFromHamas
Gaza is not occupied.
On October 7th, Hamas-ISIS terrorists infiltrated into Israel.
Women were raped, babies were burned alive, entire families were slaughtered and 240 Israelis were kidnapped.
Our people's lives are not for your free use in this childish popularity game.
Maybe you should mind your own business, or call to #FreeGazaFromHamas or just for the immediate release of all hostages.
Shame on you @GretaThunberg
Let the hostages be freed immediately. Let’s think of the children, of all the children affected by this war, as well as in Ukraine and by other conflicts: this is how their future is being killed. Let us pray that there might be the strength to say, “enough”.
#BREAKING: One minute before the Baptist Hospital in Gaza was hit, Hams announced on its own Telegram channel that they were launching their strongest rockets at the northern Israeli city of Haifa.
However, no interceptions or impacts were detected near Haifa.
Lenvatinib/Pembrolizumab is approved by the FDA for 1st line renal cancer. The significant OS signal (HR.66) is similar to other combos, but the RR (74%) and PFS (HR .39) is compelling. My opinion remains ‘pick one and use it well’, with no reason not to use Len/Pem if you want
Thrilled to finally share in peer-reviewed form: KN057 Pembrolizumab in BCG Unresponsive CIS. The first of hopefully many effective non-surgical options ahead for this disease, much work still yet to do. @UroDocAsh@PGrivasMDPhD @joostboormans
https://t.co/LNJNymXcfg
Landmark data from KN564 presented by ��@DrChoueiri - positive DFS, strong OS signal. We finally enter into a new adjuvant era in RCC. @ASCO #asco2021
חיכינו לזה! פרסום ראשון של טיפול אימונותרפי משלים בסרטן כליה, והוא חיובי! KN-564 מציג שיפור DFS עם קיטרודה משלים לאחר כריתת RCC בסיכון גבוה או גרורתי NED. סטנדרט טיפולי חדש! #ASCO21
Plenary abstracts available - Adjuvant pembrolizumab in high risk RCC has a significant DFS benefit and an early OS signal which is not yet significant. DFS: HR 0.68 (95% CI 0.53−0.87;P=0.001). OS HR 0.54 (95% CI 0.30−0.96) P=0.02.Gr3-5 AEs: 32% vs 17%: strong results #ASCO2021